MPN Alliance Australia Newsletter
Ruxolitinib available for some PV patients?
The Pharmaceutical Benefits Advisory Committee is open for comments from patients about the possible inclusion of ruxolitinib (Jakavi®) onto the PBS for some PV patients resistant or intolerant to Hydroxyurea.
If you have PV, you may wish to make a submission. It's simple - see HERE for how!